EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition

Adam Rock iD, Isa Mambetsariev, Siddhika Pareek, Jeremy Fricke iD, Xiaochen Li, Javier Arias-Romero iD, Waasil Kareem iD, Leonidas Arvanitis iD, Debora S Bruno, Stacy Gray, Ravi Salgia iD

Current Oncology · 03.10.2025 · 32 (10) · 554

DOI: 10.3390/curroncol32100554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 03.10.2025. Verfasst von Adam Rock und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Epidermal growth factor receptor (EGFR) alterations exist in 15–50% of non-small cell lung cancer (NSCLC) diagnoses. Although effective therapeutics have been developed in the form of tyrosine kinase inhibitors (TKI), various mechanisms of resistance lead to treatment failure after exposure to EGFR TKI-based therapy. Of these, histologic transformation (HT) into small cell lung cancer (SCLC) represents approximately 14% of cases.

Methods

Within a single institution, we retrospectively reviewed longitudinal data from both tissue and liquid biopsies of patients with histologic transformation after a diagnosis of EGFR-mutant NSCLC. We sought to further characterize the baseline and emergent genomic alterations after HT to SCLC in the context of TKI exposure, along with germline alterations that may contribute to lineage plasticity and outcomes.

Results

Fifteen patients were included in our analysis. Of these, EGFR exon 19 deletions were the most frequent (n = 11, 73.3%), followed by L858R (n = 3, 20%) and L861Q (n = 1, 6.7%). The median time for transformation was 17 months (95%CI, 8.9–41.9 months). The median OS of our cohort was 51.6 months (95%CI, 26.3—NE) with a median OS post-transformation of 13.4 months. Recurrent genomic alterations included TP53, Rb1, PIK3CA, and BRAF. Germline testing revealed a pathogenic alteration in FBN1, with a recurrent variant of unknown significance (VUS) in PALLD.

Conclusion

Post-transformation somatic mutation testing and germline testing at presentation revealed unique mutational profiles not previously reported in the setting of HT to SCLC. Further investigations are required to determine the optimal treatment and sequencing following HT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProtein Kinase InhibitorsLung NeoplasmsSmall Cell Lung CarcinomaCell Transformation, NeoplasticHumansMaleFemaleErbB ReceptorsMiddle AgedAgedRetrospective StudiesMutationAdultAged, 80 and over

Stichwörter der Autor:innen

EGFRgermlinenon-small cell lung cancersmall cell lung cancersomatictransformation

Substanzen

Protein Kinase InhibitorsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Division of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Department of Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Department of Medical Oncology & Therapeutics Research, City of Hope Cancer Center Atlanta, Newnan, GA 30265, USA.

ORCID-Profile: Adam Rock, Jeremy Fricke, Javier Arias-Romero, Waasil Kareem, Leonidas Arvanitis, Ravi Salgia

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health

Zitieren

APA

Rock, A., Mambetsariev, I., Pareek, S., Fricke, J., Li, X., Arias-Romero, J., Kareem, W., Arvanitis, L., Bruno, D. S., Gray, S., & Salgia, R. (2025). Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition. Current Oncology, 32(10), 554. https://doi.org/10.3390/curroncol32100554

Vancouver

Rock A, Mambetsariev I, Pareek S, Fricke J, Li X, Arias-Romero J, et al. Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition. Current Oncology. 2025;32(10):554. doi:10.3390/curroncol32100554

BibTeX
@article{Rock2025,
  author = {Rock, Adam and Mambetsariev, Isa and Pareek, Siddhika and Fricke, Jeremy and Li, Xiaochen and Arias-Romero, Javier and Kareem, Waasil and Arvanitis, Leonidas and Bruno, Debora S and Gray, Stacy and Salgia, Ravi},
  title = {Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {10},
  pages = {554},
  doi = {10.3390/curroncol32100554}
}
Kostenlos starten →